Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 32, Issue 4, Pages 793-887Publisher
IOS PRESS
DOI: 10.3233/JAD-2012-121186
Keywords
Alzheimer's disease; cognitive enhancers; memantine; memory; nootropics; receptors
Categories
Ask authors/readers for more resources
Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropicswas coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease-modifying drugs meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-beta and tau. For drugs, whose mechanism of action is not known, they are either classified according to structure, e. g., peptides, or their origin, e.g., natural products. The review covers the evolution of research in this field over the last 25 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available